4 results about "Thromboembolic disease" patented technology

The application discloses a cinnoline PAR4 antagonist and medical application thereof. The application relates to a compound of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts, esters, solvates or prodrugs thereof. The compound of the application can inhibit and prevent platelet aggregation induced by PAR4, can be used for treating and preventing thromboembolic diseases, and thus can be used as an anti-platelet drug.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

This invention belongs to the field of pharmaceutical technology and relates to platelet aggregation inhibitors, their preparation methods, and applications. This invention provides compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates, wherein R1, R2, and n are as described in the claims and specification. This invention also provides intermediates for preparing compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates. The compounds of general formula I of this invention, their pharmaceutically usable salts, tautomers, pharmaceutically usable solvates, or pharmaceutical compositions thereof have platelet-inhibiting activity and can be used to prepare platelet aggregation inhibitors, which can be used to treat thromboembolic diseases, especially cerebral infarction.

Provided are a PCSK9 antibody and the use thereof. The PCSK9 antibody can be used in the preparation of drugs for reducing lipoprotein levels in blood and for preventing or treating cardiovascular diseases or disorders and thromboembolic diseases or disorders.